WEST LAFAYETTE, IN, November 1, 2022 — Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), is pleased to announce Brennan Freeman as the Company’s Vice President, Finance and Corporate Controller, effective October 25, 2022.

Mr. Freeman joined Inotiv on July 12, 2021, and served as Corporate Controller since that time. He began his career at Ernst & Young LLP, where he held various positions, including most recently as Senior Manager – Assurance Services.

Brennan Freeman, VP, Finance and Corporate Controller

Some of Mr. Freeman’s key responsibilities as Inotiv’s new VP, Finance and Corporate Controller are:

• 🔸Preparation of consolidated financial results and compliance with SEC reporting requirements
• 🔸Amplifying Inotiv’s core values by enhancing the focus of diversity, inclusion and belonging to ensure all Inotiv colleagues around the world are welcomed, appreciated and empowered to be their authentic, best selves every day.
• 🔸Oversee all sides of accounting operations, including payables, receivables, and tax preparation and compliance
• 🔸Develop appropriate tracking methods for revenue and expenses
• 🔸Oversee development and oversight of Inotiv’s internal control structure and the compliance with the defined structure

Beth Taylor, Inotiv’s Senior Vice President of Finance and Chief Financial Officer, commented, “I have a great deal of confidence in Brennan’ s leadership capabilities, collaboration skills, experience, and qualifications to assume this important role. I look forward to continue working alongside Brennan as we continue to refine and grow the business!”

About Inotiv
Inotiv, Inc. is a leading contract research organization dedicated to providing nonclinical and analytical drug discovery and development services and research models and related products and services. The Company’s products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development, all while increasing efficiency, improving data, and reducing the cost of taking new drugs to market. Inotiv is committed to supporting discovery and development objectives as well as helping researchers realize the full potential of their critical R&D projects, all while working together to build a healthier and safer world. Further information about Inotiv can be found here: https://www.inotivco.com/.

This release may contain forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry and regulatory standards, the timing of acquisitions and the successful closing, integration and business and financial impact thereof, governmental regulations, inspections and investigations, the impact of site closures and consolidations, expansion and related efforts, and various other market and operating risks, including those detailed in the Company's filings with the U.S. Securities and Exchange Commission.